BRPI0819976A2 - composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos. - Google Patents

composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos.

Info

Publication number
BRPI0819976A2
BRPI0819976A2 BRPI0819976-0A BRPI0819976A BRPI0819976A2 BR PI0819976 A2 BRPI0819976 A2 BR PI0819976A2 BR PI0819976 A BRPI0819976 A BR PI0819976A BR PI0819976 A2 BRPI0819976 A2 BR PI0819976A2
Authority
BR
Brazil
Prior art keywords
compounds
inhibition
disease
inhibitors
isoprenyl
Prior art date
Application number
BRPI0819976-0A
Other languages
English (en)
Inventor
Lee Seung-Yub
Perez Eduardo
Rapole Keshava
Sarngadharan Gopal
B. Stock Jeffry
Stock Maxwell
Voronkov Michael
Wolanin Peter
B. Stock Gregory
Original Assignee
Signum Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signum Biosciences, Inc. filed Critical Signum Biosciences, Inc.
Publication of BRPI0819976A2 publication Critical patent/BRPI0819976A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

compostos mimético de ácido para a ini- bição de isoprenil-s-cisteinil meti l transferase, composi- ção compreendendo os mesmos, bem como uso dos ditos compostos. a presente invenção refere-se a fornecer novos compostos capazes de eficazmente inibir respostas inflamatórias que são mediadas por proteínas g ou gpcrs em neutrófilos, macrófagos e plaquetas. em particular, os compostos da presente invenção agem como inibidores de edema, inibidores de eritema e inibidores de mpo (mieloperoxidase), composições farmacêuticas contendo os mesmos compostos e o uso dos mesmos para o tratamento de doenças que pode beneficiar-se da inibição de edema, eritema e mpo, tais como inflamação (aguda ou crônica), asma, doenças autoimunes, e doença pulmonar obstrutiva crônica (copo) (por exemplo, enfisema, bronquite crônica e doença das vias aéreas pequenas, etc.), respostas inflamatórias do sistema imune, doenças de pele (por exemplo, redução da irritação de pele aguda para pacientes que sofrem de rosácea, dermatite atópica, dermatite seborreica, psoríase), síndrome do intestino irritável (por exemplo, doença de chron e colite ulcerativa, etc.), e distúrbios do sistema nervoso central (por exemplo, doença de parkinson).
BRPI0819976-0A 2007-12-03 2008-12-02 composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos. BRPI0819976A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US512907P 2007-12-03 2007-12-03
US61/005,129 2007-12-03
US586607P 2007-12-07 2007-12-07
US61/005,866 2007-12-07
US723407P 2007-12-10 2007-12-10
US61/007,234 2007-12-10
PCT/US2008/085274 WO2009073665A1 (en) 2007-12-03 2008-12-02 Acid mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase

Publications (1)

Publication Number Publication Date
BRPI0819976A2 true BRPI0819976A2 (pt) 2019-02-12

Family

ID=40718133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819976-0A BRPI0819976A2 (pt) 2007-12-03 2008-12-02 composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos.

Country Status (7)

Country Link
US (1) US20090170917A1 (pt)
EP (1) EP2240019A4 (pt)
JP (1) JP2011505384A (pt)
CN (1) CN101883487A (pt)
AU (1) AU2008333929A1 (pt)
BR (1) BRPI0819976A2 (pt)
WO (1) WO2009073665A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2432154B (en) * 2005-11-10 2010-12-29 Rhodia Uk Ltd Corrosion inhibition
EP2326619B1 (en) * 2008-08-01 2019-02-27 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
CN102209701B (zh) * 2008-11-11 2014-10-15 西格纳姆生物科学公司 异戊二烯基化合物和其方法
WO2011012283A1 (en) * 2009-07-30 2011-02-03 University Of Zurich Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
CN104610109A (zh) 2009-11-12 2015-05-13 西格纳姆生物科学公司 抗细菌剂及其组合物
WO2018132759A1 (en) * 2017-01-13 2018-07-19 Signum Biosciences, Inc. Compounds and methods use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139635A (en) * 1967-02-21 1979-02-13 L'oreal Cysteamine derivatives for oral treatment of seborrhea
US3821405A (en) * 1968-02-19 1974-06-28 Oreal Oral treatment of seborrhea and compositions for use in said treatment
US4035492A (en) * 1967-02-21 1977-07-12 L'oreal Oral treatment of seborrhea with cysteamine derivatives
US3950542A (en) * 1967-02-21 1976-04-13 L'oreal Cysteamine derivatives for oral treatment of seborrhea
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
US5202456A (en) 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
YU4602A (sh) * 1999-07-22 2005-06-10 Aventis Pharmaceuticals Inc. Farmaceutske formulacije zaštićene od dejstva mikroorganizama
AU2002249913A1 (en) * 2001-01-03 2002-08-12 President And Fellows Of Harvard College Compounds regulating cell proliferation and differentiation
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7271271B2 (en) * 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US8143425B2 (en) * 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
EP2240019A4 (en) 2011-11-16
WO2009073665A1 (en) 2009-06-11
JP2011505384A (ja) 2011-02-24
AU2008333929A1 (en) 2009-06-11
CN101883487A (zh) 2010-11-10
US20090170917A1 (en) 2009-07-02
WO2009073665A4 (en) 2009-10-01
EP2240019A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
Ren et al. Apigenin retards atherogenesis by promoting ABCA1-mediated cholesterol efflux and suppressing inflammation
BRPI0819976A2 (pt) composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos.
Kalani et al. Epigenetic impact of curcumin on stroke prevention
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
MX350010B (es) Inhibidores syk de imidazopiridinas.
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
Zong et al. Epigenetic mechanisms in chronic obstructive pulmonary disease.
BR112014026703A2 (pt) inibidores de dna-pk
BR112014027227A2 (pt) modificação alvejada de malato desidrogenase
BR112015022340A2 (pt) método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
BR112013002112A2 (pt) composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável ou n-óxido, ou um solvato ou hidrato do mesmo, ou de uma composição
UA111272C2 (uk) Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
MX2018002631A (es) Inhibidores de molecula pequeña de dyrkia y usos de los mismos.
BR112012019635A2 (pt) compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112015014701A2 (pt) derivados de benzimidazol como inibidores de quinase
BR112015022227A2 (pt) inibidores de leucotrieno a4 hidrolase
BR112012006184A2 (pt) formulações de comprimidos de ácido (z)-2-ciano-3-hidróxi-but-2-enoico-(4'-trifluormetilfenil)-amida com estabilidade aperfeiçoada
EA201290878A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
GEAP201813860A (en) Novel compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]